NCT06722729View on ClinicalTrials.gov

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Parkinson Disease
Interventions
DRUG

KDT-3594

Oral administration

DRUG

Placebo

Oral administration

Trial Locations (1)

Unknown

RECRUITING

Research Site, Multiple Locations

Sponsors
All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY

NCT06722729 - A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter